Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Atrial Fibrillation

Treatments: Drug: AZD7009, no generic name available

Study type: Interventional

Funder types: Industry

Identifiers

NCT00255281

D1461C00006

Details and patient eligibility

About

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

Enrollment: 160 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity

Exclusion criteria

• Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium <3.8 mmol/L or >5.0 mmol/L. QTc(Bazett) >450 ms. Any QRS duration >150 ms

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind